OncoSec Medical

OncoSec Medical is focused on the development of electrooncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics for the targeted delivery of the agents.In March 2018, OncoSec announced a strategic relocation of the office and lab in San Diego that was expected to provide immediate and significant cost-savings of approximately $65,000 per month.In May 2022, OncoSec Medical Incorporated announced that it is the recipient of the 2022 Vanguard Award presented by the Triple Negative Breast Cancer Foundation.In May 2023, OncoSec Medical Inc announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, with gross proceeds of $1.33 million.In April 2023, OncoSec Medical Inc closed its registered direct offering and issued unregistered warrants to purchase up to 1,582,932 shares of common stock, with